Overview

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Status:
Terminated

Trial end date:
2018-01-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients with ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.

Phase:

Phase 1

Details

Lead Sponsor:

Alnylam Pharmaceuticals

Treatments:

Alpha 1-Antitrypsin
Protein C Inhibitor